Angle PLC Announces Parsortix Used in Research Paper from ETH Zurich
ANGLE plc has announced breakthrough research from ETH Zurich published in Nature Medicine, featuring their Parsortix system in a Phase 1 clinical trial for metastatic breast cancer treatment. The study used FDA-approved drug digoxin and demonstrated the Parsortix system's critical role in identifying patients with CTC clusters for targeted treatment.
The trial achieved its primary endpoint, showing significant reduction in CTC cluster size in the treatment group. This proof-of-principle study opens possibilities for developing novel drugs preventing metastasis. Professor Aceto's lab has co-founded PAGE Therapeutics to develop compounds effective at disassociating CTC clusters, with Parsortix expected to play a important role in future development.
The research is particularly significant as metastasis accounts for the majority of cancer-related deaths. The Parsortix system's unique ability to capture CTC clusters makes it valuable for developing drugs targeting metastatic spread, potentially improving patient outcomes across all solid tumors.
ANGLE plc ha annunciato ricerche innovative dall'ETH Zurigo pubblicate su Nature Medicine, che presentano il loro sistema Parsortix in una sperimentazione clinica di Fase 1 per il trattamento del cancro al seno metastatico. Lo studio ha utilizzato il farmaco approvato dalla FDA digossina e ha dimostrato il ruolo cruciale del sistema Parsortix nell'identificare i pazienti con gruppi di CTC per un trattamento mirato.
La sperimentazione ha raggiunto il suo obiettivo primario, mostrando una significativa riduzione della dimensione dei gruppi di CTC nel gruppo di trattamento. Questo studio di prova del principio apre possibilità per lo sviluppo di nuovi farmaci in grado di prevenire la metastasi. Il laboratorio del Professor Aceto ha co-fondato PAGE Therapeutics per sviluppare composti efficaci nel dissociare i gruppi di CTC, con il Parsortix che si prevede giocherà un ruolo importante nel futuro sviluppo.
La ricerca è particolarmente significativa poiché la metastasi rappresenta la maggior parte delle morti correlate al cancro. L'unicità del sistema Parsortix nell'acquisire gruppi di CTC lo rende prezioso per lo sviluppo di farmaci mirati alla diffusione metastatica, potenzialmente migliorando i risultati per i pazienti affetti da tutti i tumori solidi.
ANGLE plc ha anunciado una investigación innovadora del ETH Zurich publicada en Nature Medicine, que presenta su sistema Parsortix en un ensayo clínico de Fase 1 para el tratamiento del cáncer de mama metastásico. El estudio utilizó el medicamento aprobado por la FDA digoxina y demostró el papel crítico del sistema Parsortix en la identificación de pacientes con grupos de CTC para un tratamiento dirigido.
El ensayo alcanzó su objetivo primario, mostrando una reducción significativa en el tamaño de los grupos de CTC en el grupo de tratamiento. Este estudio de prueba de principio abre posibilidades para el desarrollo de nuevos medicamentos que prevengan la metastasis. El laboratorio del Profesor Aceto ha co-fundado PAGE Therapeutics para desarrollar compuestos efectivos en disociar los grupos de CTC, con Parsortix que se espera desempeñe un papel importante en el desarrollo futuro.
La investigación es particularmente significativa ya que la metastasis representa la mayoría de las muertes relacionadas con el cáncer. La capacidad única del sistema Parsortix para capturar grupos de CTC lo hace valioso para el desarrollo de medicamentos dirigidos a la propagación metastásica, mejorando potencialmente los resultados para los pacientes en todos los tumores sólidos.
ANGLE plc는 ETH 취리히의 혁신적인 연구를 발표했으며, 이는 Nature Medicine에 게재되었고, 전이성 유방암 치료를 위한 1상 임상 시험에서 그들의 Parsortix 시스템을 다루고 있습니다. 이 연구는 FDA 승인 약물 디고신을 사용했고, Parsortix 시스템이 표적 치료를 위한 CTC 클러스터 환자 식별에 중요한 역할을 한다는 것을 증명했습니다.
임상 시험은 주요 목표를 달성하였으며, 치료 그룹에서 CTC 클러스터 크기의 유의미한 감소를 보여주었습니다. 이 원리 검증 연구는 전이를 예방할 수 있는 새로운 약물 개발의 가능성을 열어줍니다. 아체토 교수의 연구실은 CTC 클러스터를 분리하는데 효과적인 화합물을 개발하기 위해 PAGE Therapeutics를 공동 설립하였으며, Parsortix가 향후 개발에서 중요한 역할을 할 것으로 기대됩니다.
이 연구는 전이가 암 관련 사망의 대부분을 차지한다는 점에서 특히 중요합니다. CTC 클러스터를 포착하는 Parsortix 시스템의 독특한 능력은 전이 확산을 타깃으로 하는 약물 개발에 소중한 자원으로 작용하여, 모든 고형 종양에서 환자 결과를 향상시킬 가능성을 가지고 있습니다.
ANGLE plc a annoncé des recherches révolutionnaires de l'ETH Zurich publiées dans Nature Medicine, présentant leur système Parsortix dans un essai clinique de phase 1 pour le traitement du cancer du sein métastatique. L'étude a utilisé le médicament approuvé par la FDA digoxine et a démontré le rôle essentiel du système Parsortix dans l'identification des patients avec des grappes de CTC pour un traitement ciblé.
L'essai a atteint son objectif principal, montrant une réduction significative de la taille des grappes de CTC dans le groupe de traitement. Cette étude de preuve de concept ouvre des possibilités pour le développement de nouveaux médicaments visant à prévenir la métastase. Le laboratoire du Professeur Aceto a cofondé PAGE Therapeutics pour développer des composés efficaces pour dissocier les grappes de CTC, avec Parsortix qui devrait jouer un rôle important dans le développement futur.
La recherche est particulièrement significative car la métastase représente la majorité des décès liés au cancer. La capacité unique du système Parsortix à capturer les grappes de CTC le rend précieux pour le développement de médicaments ciblant la propagation métastatique, améliorant potentiellement les résultats pour les patients atteints de toutes les tumeurs solides.
ANGLE plc hat bahnbrechende Forschungen vom ETH Zürich angekündigt, die in Nature Medicine veröffentlicht wurden und ihr Parsortix-System in einer klinischen Phase-1-Studie zur Behandlung von metastasiertem Brustkrebs präsentieren. Die Studie verwendete das von der FDA zugelassene Medikament Digoxin und zeigte die entscheidende Rolle des Parsortix-Systems bei der Identifizierung von Patienten mit CTC-Clustern für eine gezielte Behandlung.
Die Studie erreichte ihr primäres Ziel und zeigte eine signifikante Reduktion der Größe der CTC-Cluster in der Behandlungsgruppe. Diese Machbarkeitsstudie eröffnet die Möglichkeit zur Entwicklung neuartiger Medikamente zur Verhinderung von Metastasen. Das Labor von Professor Aceto hat PAGE Therapeutics mitbegründet, um Verbindungen zu entwickeln, die wirksam sind bei der Dissoziation von CTC-Clustern, wobei Parsortix eine wichtige Rolle in der zukünftigen Entwicklung spielen wird.
Die Forschung ist besonders bedeutend, da Metastasen die Mehrheit der krebsbedingten Todesfälle ausmachen. Die einzigartige Fähigkeit des Parsortix-Systems, CTC-Cluster zu erfassen, macht es wertvoll für die Entwicklung von Arzneimitteln, die das metastatische Wachstum anvisieren und potenziell die Patientenergebnisse bei allen soliden Tumoren verbessern könnten.
- Successfully achieved primary endpoint in Phase 1 trial showing reduction in CTC cluster size
- Parsortix system demonstrated critical capability in patient selection for targeted treatment
- Partnership with PAGE Therapeutics for future drug development
- Publication in prestigious Nature Medicine journal validates technology
- Clinical outcomes were not assessed in this proof-of-concept study
- Treatment currently to metastatic breast cancer patients
CLINICAL TRIAL POWERED BY PARSORTIX SYSTEM PROVIDES FIRST-IN-CLASS data FOR NOVEL APPROACH TO CANCER treatment
Parsortix system used to identify patients with highly metastatic CTC clusters for targeted treatment
New treatment strategy provides 'uncharted opportunity' to target metastasis responsible for the vast majority of cancer deaths
GUILDFORD, SURREY / ACCESS Newswire / January 24, 2025 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, is delighted to announce the publication of breakthrough research from Professor Nicola Aceto's team at the research university ETH Zurich, Switzerland, in the journal Nature Medicine.
The publication reports on an interventional multi-centre Phase 1 clinical trial using the repurposed, FDA approved drug, digoxin, to treat metastatic breast cancer patients. The Parsortix® system played a critical role in selecting patients for this targeted treatment by identifying those who were positive for CTC clusters (two or more tumour cells travelling together in the bloodstream). This enabled researchers to enrol only patients who might benefit from digoxin treatment, which has been shown to dissociate highly metastatic CTC clusters in preclinical studies1.
The primary endpoint for the trial was successfully achieved with a significant reduction in CTC cluster size reported in the treatment group. This proof-of-principle study paves the way for the development of a novel class of drugs that prevent or suppress the development of metastasis. The Parsortix system is already well established in the Aceto Lab and Professor Aceto has co-founded the company PAGE Therapeutics (pagetherapeutics.com) to develop novel compounds which are highly effective at disassociating CTC clusters. It is anticipated that the Parsortix system will play a crucial role in the pre-clinical and clinical development of these compounds, including dose finding and selection of the most appropriate patients for clinical trials.
Professor Nicola Aceto, Aceto Lab, ETH Zurich, commented:
"Given that the spread of cancer accounts for the vast majority of cancer-related deaths, the effective prevention and suppression of metastasis is an elusive goal for clinicians worldwide. Standard-of-care treatments are typically developed based on their cytotoxic activity and are not necessarily designed to interfere with metastasis-relevant mechanisms. Consequently, there is an uncharted opportunity for the development of targeted agents that disrupt the causes of metastasis themselves.
While clinical outcomes were not assessed in this proof-of-concept study, the trial provides first-in-class evidence that supports the development of novel treatments targeting the metastatic process."
ANGLE's Chief Scientific Officer, Karen Miller, commented:
"We are delighted to report on this first-in-class treatment approach reported by the Aceto Lab which has the potential to significantly reduce the burden of metastatic disease and improve patient outcomes. Given its unique design and ability to capture CTC clusters, we anticipate that the Parsortix system will be a crucial component for the development of drugs targeting the metastatic cascade by facilitating the selection of patients who are most likely to respond to treatment and allow continuous monitoring to determine the pharmacodynamic effects of the drugs. Alongside our ongoing collaboration with ETH Zurich, we look forward to working with PAGE Therapeutics to support their development drugs targeting metastatic spread."
The peer-reviewed publication is published in the journal Nature Medicine and available for review at https://angleplc.com/resources/publications/
Background information
CTCs are intact, living cancer cells circulating in the blood and are well established as the precursors of metastasis. Whilst individual CTCs face formidable obstacles in the bloodstream, including attack by immune cells and disruptive fluid shear forces, the aggregation of cells into clusters has been shown to enhance metastatic potential by up to 100 times through enhanced immune evasion, proliferative advantage and increased cell adhesion which supports metastatic seeding. Furthermore, CTC clusters have been found to exhibit increased resistance to cancer drugs, making them harder to treat.
With the vast majority of cancer deaths caused by the metastatic spread of the primary cancer to other organs, such as bones, liver, lungs and brain, a targeted treatment to disassociate CTC clusters could enable CTCs to be targeted by the body's own immune system and increase the effectiveness of existing cytotoxic treatments. This could result in a profound improvement in treatment success and patient survival across all solid tumours.
The patented Parsortix system enables highly sensitive, marker-independent CTC isolation from a standard blood sample. It is a unique system, capable of harvesting large CTC clusters for downstream analysis which remain intact, and with their associated immune cells, for visualisation and analysis enabling the development and implementation of a completely new method for suppressing cancer metastasis.
Using ANGLE's Parsortix system, the Aceto lab has demonstrated that, in mouse models, disassociation of CTC clusters using an ATPase inhibitor (like the FDA cleared cardiac drug, digoxin, used to treat heart failure and atrial fibrillation) leads to a near total elimination of metastatic cancer spread with treated animals showing 80x less metastasis compared with untreated animals (peer-reviewed publication in the journal Cellhttps://angleplc.com/wp-content/uploads/2023/05/PIIS009286741831571X.pdf). The new study, demonstrating CTC cluster disassociation in breast cancer patients, opens up the potential to evaluate reduction in cancer metastasis and increased overall survival in breast cancer patients with a new class of drugs under-pinned by the assessment of CTC clusters using the Parsortix system.
1. Gkountela et al. Circulating tumor cell clustering shapes DNA methylation to enable metastasis seeding. Cell (2022)
For further information:
ANGLE plc | +44 (0) 1483 343434 |
Andrew Newland, Chief Executive |
|
|
|
|
|
|
|
|
|
For Research Use Only. Not for use in diagnostic procedures.
For Frequently Used Terms, please see the Company's website on https://angleplc.com/investor-relations/glossary/
Notes for editors
About ANGLE plc
ANGLE is a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology using a simple blood sample. ANGLE's FDA cleared and patent protected CTC harvesting technology known as the Parsortix® PC1 System enables complete downstream analysis of the sample including whole cell imaging and proteomic analysis and full genomic and transcriptomic molecular analysis.
ANGLE's commercial businesses are focusing on clinical services and diagnostic products. The clinical services business is offered through ANGLE's GCLP-compliant laboratories. Services include custom made assay development and clinical trial testing for pharma. Products include the Parsortix system, associated consumables and assays.
Over 100 peer-reviewed publications have demonstrated the performance of the Parsortix system. For more information, visit www.angleplc.com
Any reference to regulatory authorisations such as FDA clearance, CE marking or UK MHRA registration shall be read in conjunction with the full intended use of the product:
The Parsortix® PC1 system is an in vitro diagnostic device intended to enrich circulating tumor cells (CTCs) from peripheral blood collected in K2EDTA tubes from patients diagnosed with metastatic breast cancer. The system employs a microfluidic chamber (a Parsortix cell separation cassette) to capture cells of a certain size and deformability from the population of cells present in blood. The cells retained in the cassette are harvested by the Parsortix PC1 system for use in subsequent downstream assays. The end user is responsible for the validation of any downstream assay. The standalone device, as indicated, does not identify, enumerate or characterize CTCs and cannot be used to make any diagnostic/prognostic claims for CTCs, including monitoring indications or as an aid in any disease management and/or treatment decisions.
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
SOURCE: ANGLE plc
View the original press release on ACCESS Newswire
FAQ
What were the main results of ANPCY's Phase 1 trial with digoxin?
How does ANPCY's Parsortix system help in cancer treatment selection?
What is the significance of CTC clusters in ANPCY's cancer research?
What is the collaboration between ANPCY and PAGE Therapeutics?
How effective was the CTC cluster treatment in preclinical studies for ANPCY?
